A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF V114 IN HEALTHY INFANTS (PNEU-LINK)/ PROTOCOL 031-00

Intervention/treatment:
V114
Medical condition:
PNEUMOCOCCAL DISEASE
Protocol code:
V114-031
Control number:
221060
Status:
Closed
Approved:
November 28, 2018
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT03692871
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
42 Days to 90 Days
Accepts healthy volunteers: Yes

Contacts and locations

Contact
Name
Clinical Trials Disclosure
Organization
Merck Sharp & Dohme LLC
Phone:
1-800-672-6372
Sponsor
MERCK CANADA INC

Locations

Alberta

Alberta Children s Hospital ( Site 0048)
Calgary, Alberta, T3B 6A8

British Columbia

Vaccine Evaluation Center BC Children s Hospital Research Institute ( Site 0046)
Vancouver, British Columbia, V5Z 4H4

Nova Scotia

IWK Health Centre [Halifax, Canada] ( Site 0043)
Halifax, Nova Scotia, B3K 6R8

Ontario

Hamilton Medical Research Group ( Site 0049)
Hamilton, Ontario, L8M 1K7
Medicor Research Inc. ( Site 0041)
Greater Sudbury, Ontario, P3A 1Y8

Quebec

CHUQ - Unite de Recherche en Sante Publique ( Site 0042)
Québec, Quebec, G1E 7G9
CHU Sainte Justine ( Site 0047)
Montreal, Quebec, H3T 1C5
McGill University Health Centre - Vaccine Study Centre ( Site 0045)
Pierrefonds, Quebec, H9H 4Y6

Results

See the results from the trial NCT03692871. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?